CE-mark for removable vena cava filter:
This article was originally published in Clinica
NMT Medical has CE-marked what it claims to be the first removable vena cava filter for preventing pulmonary embolism. The Recovery filter, which can be easily removed with a catheter removal system early after implantation, may also be left as a permanent filter if desired, said the Boston, Massachusetts-based company. It added that the ability to remove the filter early after implantation could lead to the use of vena cava filters in a broader range of indications. The new device will be distributed in Europe by the Peripheral Technologies division of CR Bard.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.